Direxion Daily S&P Biotech Bear 3X ETF
LABD
17 hedge funds and large institutions have $13.5M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.
108% more call options, than puts
Call options by funds: $15.2M | Put options by funds: $7.3M
6% less funds holding
Funds holding: 18 → 17 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
48.98% less ownership
Funds ownership: 88.66% → 39.68% (-49%)
68% less capital invested
Capital invested by funds: $41.8M → $13.5M (-$28.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$1.36M |
| 2 |
Goldman Sachs
New York
|
+$929K |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
+$619K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$581K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.1M |
| 2 |
Jane Street
New York
|
-$7.13M |
| 3 |
VF
Virtu Financial
New York
|
-$4.22M |
| 4 |
HF
HRT Financial
New York
|
-$2.16M |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$1.25M |
LABD Hedge Fund Activity: Q4 2022 in Review
17 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q4 2022, worth a combined $13.5M — down 68% from $41.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LABD and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was IMC Chicago, opening a new position worth an estimated $1.36M. The largest seller was Susquehanna International Group, cutting an estimated $10.1M.
- 17 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q4 2022, down from 18 in Q3 2022.
- Funds reported $13.5M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q4 2022, down 68% quarter-over-quarter.
- 5 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q4 2022 and 6 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q4 2022 was IMC Chicago, an estimated $1.36M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q4 2022 was Susquehanna International Group, an estimated $10.1M sold.
Based on aggregated 13F filings for Q4 2022.